secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001193125-25-261612
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Therapeutics restructures, cuts 30% of workforce, pauses solid tumor trial, extends cash runway to H2 2027
--------------------------------------------------------------------------------

- FDA agrees to pivotal study design for TSC-101 in AML/MDS; trial to start Q2 2026.
- Workforce reduced by ~30% (66 roles); expects $2.3M severance charge in Q4 2025.
- Strategic prioritization yields ~$45M annual cost savings in 2026-27; cash runway extended to H2 2027.
- Pauses further enrollment in solid tumor Phase 1 PLEXI-T trial; to present initial data Q1 2026.
- First two patients dosed with multiplex TCR-T in solid tumors; shifting preclinical focus to in vivo engineering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000119312525261612/0001193125-25-261612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000119312525261612/d873161d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-261612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer